Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
Conditions
Keywords
advanced pancreatic cancer, palliative chemotherapy, first-line therapy, capecitabine, oxaliplatin, gemcitabine, dose-finding study, Phase II
Brief summary
Gemcitabine is the mainstay of palliative chemotherapy for patients with advanced pancreatic cancer (APC). Recent randomized trials have shown increased clinical benefit with the addition of oxaliplatin and prolonged median survival with the addition of capecitabine to gemcitabine. Gemcitabine, capecitabine and oxaliplatin are 3 newer, well tolerated anticancer drugs with mild and non-overlapping toxicity profiles. We therefore propose a dose-finding and safety study of the triple combination gemcitabine, capecitabine and oxaliplatin in patients with APC (Phase I part), followed by a phase II part to assess preliminary efficacy of this triple combination.
Detailed description
Primary Objectives: * Phase I: to determine the maximum tolerated dose (MTD) of oxaliplatin in combination with gemcitabine and capecitabine (GEMOXEL) in patients with APC * Phase II: to assess any anti-tumor activity of GEMOXEL in patients with APC Secondary Objectives: * to assess toxicity and safety of the combination treatment GEMOXEL in patients with APC Primary Endpoints: * Phase I: Dose-limiting toxicity * Phase II: Objective tumor response Secondary Endpoints: * Toxicity at MTD according to NCI CTC 3.0 * Progression-free survival and Overall Survival
Interventions
DRUGgemcitabine, oxaliplatin, capecitabine
gemcitabine day 1 and 8, oxaliplatin day 1, capecitabine days 1-14, q3weeks
Sponsors
Swiss National Science Foundation
Swiss Cancer League
Roche Pharma AG
Sanofi
University Hospital, Basel, Switzerland
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Cytologically or histologically confirmed adenocarcinoma of the exocrine pancreas * Disease non-resectable and locally advanced or metastatic * Measurable disease or evaluable disease i.e. tumor marker CA19-9 at baseline ≥ 1.5 x upper limit of normal (ULN) * Age \>18 years * Karnofsky performance status ≥ 60% * Life expectancy of at least 3 months * Written informed consent * Willing and able to comply with the protocol for the duration of the study
Exclusion criteria
* Prior chemotherapy for pancreatic cancer * Prior adjuvant radio- or radiochemotherapy for pancreatic cancer within 12 months of inclusion * Known CNS metastases at the time of enrollment * Neutrophil count ≤ 1.5 x109/l, platelet count ≤100 x109/l, hemoglobin ≤ 10g/dl * Serum creatinine \> 1.25 x ULN * ASAT, ALAT and alkaline phosphatase \> 2.5 ULN or \> 5 ULN in the presence of liver metastasis, Bilirubin \> 1.5 ULN (after treatment of obstructive jaundice eg. stent) * Pregnant or breast feeding women (women of childbearing potential must have a negative pregnancy test at baseline) * Men and women of reproductive potential who are not using an effective method of contraception * Clinically significant cardiac disease (NYHA III-IV) or myocardial infarction within the last 12 months * Neurological disease with dys-/paraesthesias \> grade 1 according to NCI CTC * Any serious concomitant disorder incompatible with the trial (in the judgement of the investigator) * Psychiatric disability thought to be clinically significant in the opinion of the investigator precluding informed consent or interfering with compliance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | 6 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival and overall survival | 3 months |
Countries
Switzerland
Outcome results
None listed